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mechanical measurements on single scaffold struts were also per-
formed to evaluate the mechanical response of individual struts.
RESULTS 3.0mm and 3.5mm scaffold sizes could be post-expanded
up to 1 mm above their nominal diameters without any strut fracture
when deployed without an external constraining model. Over-
expansion with balloon sizes 1.5 mm above the scaffold nominal
diameter produced strut fractures in both sizes: 3.0mm scaffolds
oversized with NC balloon resulted in more strut fracture sites (on
average 12.7  3.9) as compared to oversized 3.5mm scaffolds
(1.31.2). Importantly, when overexpansion of a series of 3.0mm and
3.5mm scaffolds was repeated using a constrained silicon lesion
model, only post-expansion with NC balloon 0.5mm larger than
nominal size could be performed without causing strut fractures. The
point force single strut compression analysis shows that post-dilated
rings with fractures had the lowest local focal strength; overexpanded
ring segments without fractures had also a lower focal mechanical
strength than normal segments (expanded at nominal pressure).
Maximum point force measured for fractured, overexpanded without
fracture and normal ring were respectively: 0.17, 0.29 and 0.44 N for
BVS 3.0mm size (p < 0.01); and 0.19, 0.30 and 0.33 N for BVS 3.5mm
size (p < 0.01).
CONCLUSIONS In our experiments, only overexpansion with 0.5mm
NC balloon was feasible for BVS deployed inside an arterial lesion
model. Over-expansion of the BVS scaffold beyond recommended
post-dilation limits can lead to strut disconnections and local loss of
mechanical support.
CATEGORIES CORONARY: Bioresorbable Vascular Scaffolds
KEYWORDS Bifurcation stenting, Bioabsorbable scaffolds, Post-
dilatation
TCT-529
Incidence of persistent, resolved, and late incomplete scaffold apposition
after bioresorbable scaffold implantation in ST-segment elevation
myocardial infarction. A BVS-STEMI-ﬁrst substudy
Antonios Karanasos,1 Nicolas M. Van Mieghem,1 Hector Garcia-Garcia,1
Roberto Diletti,1 Cordula Felix,1 Jors N. van der Sijde,1 Jiang-Ming Fam,1
Yuki Ishibashi,1 Peter De Jaegere,1 Patrick W. Serruys,1
Yoshinobu Onuma,1 Felix Zijlstra,1 Evelyn Regar,1 Robert J. Van Geuns1
1Thoraxcenter, Erasmus MC, Rotterdam, Netherlands
BACKGROUND The natural history of incomplete scaffold implanta-
tion (ISA) after BVS implantation in thrombotic lesions of STEMI has
not been elucidated. We evaluated the incidence of persistent,
resolved and late ISA after BVS implantation in STEMI.
METHODS The BVS-STEMI–ﬁrst is a cohort study that enrolled 39
consecutive patients previously admitted with STEMI and treated
with BVS at the index procedure that consented to undergo invasive
follow-up by angiography and OCT at 6 months. Twenty of thirty nine
patients had also undergone OCT post implantation. In this subgroup,
serial analysis of OCT parameters was performed. Moreover, all mal-
apposed struts were identiﬁed on a frame-level basis (0.2mm interval)
for both pullbacks, and plotted in spread-out maps. The presence of
persistent, resolved, and late ISA was then estimated on a scaffold
level, by visual assessment of the maps and inspection of synchro-
nized pullbacks. Persistent ISA was deﬁned as presence of malap-
posed struts both at baseline and follow-up, resolved as malapposed
struts at baseline that were apposed at follow-up, while late as new
occurrence of malapposed struts at follow-up.
RESULTS Mean and minimal lumen area were reduced at follow-up
(p<0.001). There was no signiﬁcant difference for proximal or distal
reference lumen area, or for scaffold area. The number of malapposed
struts was non-signiﬁcantly reduced from baseline to follow-up (1.4%
vs.0.8%, p¼0.16). Malapposition distance increased from baseline to
follow-up (p<0.001), however there was no signiﬁcant difference in
the mean ISA area between the two intervals (p¼0.48). Spread-out
maps illustrating strut apposition post-implantation and at follow-up
are presented in the Figure. There were 3 patients (15%) with persis-
tent ISA, 11 patients (55%) with resolved ISA, and 6 patients (30%)
with late ISA.Post-implantation Follow-up p-valueMean Lumen
area(mm2)7.541.72 6.771.98 <0.001Minimal Lumen
area(mm2)5.811.49 4.891.92 <0.001Proximal Reference
area(mm2)7.302.08 6.692.52 0.10Distal Reference
area(mm2)6.413.22 7.213.67 0.29Mean Scaffold/Stent
area(mm2)8.011.78 8.271.98 0.17Min Scaffold/Stent
area(mm2)6.581.89 6.481.97 0.66Mean ISA area(mm2) 0 [0-0.027] 0 [0-0.034] 0.48Scaffold/stent-level
ISA(>5%) n(%)3(15.0) 1(5.0) 0.33Strut-level analysisStruts analyzed 4521 5227Malapposed struts 65 (1.44) 43 (0.82) 0.16Malapposition
distance(mm)210[130-400] 818[518-1238] <0.001CONCLUSIONS In the follow-up of BVS in STEMI, the majority of
cases with acute ISA are resolved. However, a fraction might remain
malapposed, while the incidence of late ISA is not negligible. Further
studies are warranted to evaluate the prognostic signiﬁcance of these
ﬁndings.
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BACKGROUND The ﬁrst commercially available bioresorbable scaf-
fold (BRS) Absorb has strut thickness of 150 microns, signiﬁcantly
more than contemporary drug-eluting stents. As such, it has potential
for lower deliverability and for higher thrombogenicity. Therefore,
decreasing the BRS strut thickness with no adverse effect on its
biomechanics appears desirable. In this study, we aimed to evaluate
the biological efﬁcacy of a novel sirolimus-eluting BRS (Amaranth
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micron) in a porcine coronary artery model.
METHODS Fifty-four coronary arteries of 18 Yucatan mini-swine
received either sirolimus-eluting BRS with regular strut thickness (150
mm, n¼16), lower strut thickness (120 mm, n¼16) or BVS (Absorb, n¼16)
were harvested for histopathology following imaging with angiog-
raphy and optical coherence tomography (OCT) at 28 (n¼8 for each
group) and 90 days (n¼8 for each group).
RESULTS At 28 days, 120mm-BRS showed less % diameter stenosis
(128%) by angiography compared to 150mm-BRS (1913%) and BVS
(2712%, p<0.05). Histopathology revealed smaller neointimal area
(1.680.30 mm2 vs. 150mm-BRS 2.080.50 mm2, and BVS
2.570.66mm2, p¼0.007) and % Area Stenosis (AS) in 120mm-BRS
group as well; both BRS groups had lower peri-strut inﬂammation
score compared to the BVS group (150mm-BRS: 00, 120mm-BRS:
0.170.36 vs. BVS: 0.420.39, p¼0.04). At 90 days, OCT and histo-
logical evaluation showed comparable neointimal formation (%AS:
150mm-BRS: 366%, 120mm-BRS: 3110% vs. BVS: 3814%, p¼0.40)
and comparable qualitative features of arterial healing between both
BRS groups and BVS.
CONCLUSIONS The novel sirolimus-eluting BRS with thinner (120
mm) struts showed adequate acute and chronic biomechanical
behavior and durability when compared to regular strut BRS and BVS,
and a favorable effect on neointimal inhibition and healing response
up to 90 days after implantation.
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BACKGROUND Due to the inherent limitations of bioabsorbable
polymeric materials, overexpansion may be very limited for some
bioresorbable scaffolds (BRS) such as the benchmark Absorb BVS. The
unique biomechanical properties of the novel sirolimus eluting BRS
(Amaranth Medical, Mountain View, CA) may allow it to be safely
upsized. The aim of the study was to evaluate the biomechanical
properties and healing of the sirolimus eluting BRS that have been
postdilated by 0.55 and 0.8mm beyond the nominal diameters within
the pressure-diameter compliance chart range.
METHODS Twenty eight coronary arteries of 8 healthy Yucatan min-
iswine underwent implantation of novel sirolimus eluting BRS.
Upsizing by postdilation was performed up to 0.55 mm (PLUS 0.55,
n¼6) or up to 0.8 mm (PLUS 0.8 n¼6) in a manner maintaining
consistent stent-to-artery ratio of average 110%, thus ensuring only
overexpansion of the scaffold but consistent level of arterial injury.
Non postdilated segments served as control (Control, n¼ 16). OCT and
angiographic follow up were performed at 28 and 90 days follow up.
RESULTS There was no statistical difference between tested groups in
terms of acute recoil (PLUS 0.55: 9.55.5%, PLUS 0.8: 9.77.6%,
Control 59.5%, p¼0.45). QCA analysis after 28 days showed similar
late lumen loss (PLUS 0.55: 0.480.17, PLUS 0.8: 0.290.29, Control:
0.650.50 mm, p¼0.22), % diameter stenosis was smaller in PLUS 0.8
compared to Control group (PLUS 0.55: 18.69.15%, PLUS 0.8:
102.02%, Control: 24.65.69, p<0.01). 90-day angiographic out-
comes were comparable in terms of late lumen loss (PLUS 0.55:
0.580.29, PLUS 0.8: 0.380.2, Control: 0.430.43 mm, p¼0.42) and
% diameter stenosis (PLUS 0.55: 179.3%, PLUS 0.8: 17.17.1%, Con-
trol: 18.212.5, p¼0.97). OCT analysis showed comparable neoinitmal
area (PLUS 0.55: 2.20.89, PLUS 0.8: 1.320.57, Control:
2.110.87 mm2, p¼0.13) and neointimal thickness (PLUS 0.55:
0.250.1, PLUS 0.8: 0.140.06, Control: 0.250.1 mm, p¼0.06) at 90
days follow up. No scaffold fractures were observed in any of the
studied groups.
CONCLUSIONS Overexpansion up to 0.8mm of novel, high strength
sirolimus eluting BRS is not associated with worse angiographic out-
comes, neointimal formation or biomechanical issues such as stent
deformation or fracture, neither acutely nor chronically.
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BACKGROUND Previous studies have suggested that neointimal
growth and strut coverage is reduced in patients with acute coronary
syndrome (ACS) that receive metallic stents. The BVS is a novel
technology and use of more biocompatible devices may facilitate early
neointimal growth and subsequent earlier strut coverage. We aimed to
assess whether neointimal growth is affected by clinical presentation,
in a population of patients undergoing bioresorbable vascular scaffold
(BVS) implantation.
METHODS BVS were implanted in patients either for stable angina
(SA) or ACS using optical coherence tomography (OCT) guidance.
Repeat OCT was performed at follow-up (median 74 days), and BVS
analyzed at 1mm longitudinal intervals. OCT analysis (Figure)
included measures of scaffold, luminal and ﬂow area, as well as
assessment of strut apposition, coverage and neointimal growth.
RESULTS In total, 29 BVS were included in the analysis (62%
following ACS). There were no differences between procedural or
lesion characteristics between groups. Post-deployment, all BVS
achieved >90% predicted scaffold area with only 1.64% struts classi-
ﬁed as incompletely apposed at baseline, compared with 0.47% at
follow-up (p¼0.006). Reductions in mean scaffold (-4.0%, p¼0.01)
and ﬂow (-8.4%, p<0.001) areas were observed at follow-up, with
larger reductions in mean ﬂow area for stable patients (SA -14.514.2
vs. ACS -4.97.9%, p¼0.03). ACS patients had reduced neointimal
growth (0.510.18 vs. 0.870.37mm2, p¼0.002), and increased per-
centage of uncovered struts (2.681.67% vs. 1.430.87%, p¼0.015).
CONCLUSIONS Neointimal growth and strut coverage is reduced
following ACS in patients receiving BVS at an earlier timepoint than
previously studied. This is consistent with studies in metallic stents
and suggest use of more biocompatible devices may not necessarily
improve early strut coverage.
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